Roche

News

ADA: Lilly's weight-loss reveal, and wannabes display wares

Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.

News

Roche doubles down on BTK with $2.3bn Nurix deal

Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.

News

Roche develops Bundibugyo Ebola test in six days

A PCR diagnostic developed by Roche for the Bundibugyo form of Ebola is being offered to health systems at the front lines of the current outbreak.

R&D

The changing multiple sclerosis landscape: Earlier diagnosis...

Multiple sclerosis (MS) is undergoing a meaningful evolution in how it is understood, diagnosed, and managed.

News

Roche launches liver disease algorithm panel

Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with chronic liver disease.

News

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche's Elevidys.

ADA: Lilly's weight-loss reveal, and wannabes display wares

Roche doubles down on BTK with $2.3bn Nurix deal

Roche develops Bundibugyo Ebola test in six days

The changing multiple sclerosis landscape: Earlier diagnosis...

Roche launches liver disease algorithm panel

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

Sanofi abandons phase 3 trial of neurology drug riliprubart

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks